ALK-Abelló
131 DKK -0.15%HC Andersen Capital receives payment from ALK-Abelló for a DigitalIR/Corporate Visibility agreement. See disclaimer.
10 investors are following this company
ALK-Abelló is a developer of allergy and immunotherapy. Operations are held on a global level and the products are sold both as a vaccine and in tablet form. A large part of the business consists of research and development in the work area, where the company actively works with the diagnosis and treatment of recurring allergy problems. The company was founded in 1923 and is headquartered in Hørsholm, Denmark.
Revenue
4.82B
EBIT %
13.81 %
P/E
59.55
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Copenhagen
ALK B
Daily low / high price
127 / 137.5
DKK
Market cap
29.19B DKK
Turnover
54.37M DKK
Volume
413K
Latest videos
Financial calendar
Interim report
03.05.2024
Interim report
23.08.2024
Interim report
14.11.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
The Lundbeck Foundation | 40.3 % | 67.2 % |
The Danish Labour Market Supplementary Pension ( ATP) | 7.5 % | 4.1 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Three-month interim report (Q1) 2024 (unaudited) - English version only
ALK upgrades its full-year revenue outlook
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools